Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2025 08:45 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius regains compliance with all Nasdaq listing requirements
September 09, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 14, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
July 14, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

Salarius Pharmaceuticals granted additional extention to regain Nasdaq compliance
July 09, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy...
April 16, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide...
March 26, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of...
March 24, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating...
February 03, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial...
January 13, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding...